Konecny GE - Search Results

1

Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.

Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, Slamon D, Velculescu VE, Scharpf RB. Papp E, et al. Among authors: konecny ge. Cell Rep. 2018 Nov 27;25(9):2617-2633. doi: 10.1016/j.celrep.2018.10.096. Cell Rep. 2018. PMID: 30485824 Free PMC article.

2

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

Pegram MD, Konecny G, Slamon DJ. Pegram MD, et al. Cancer Treat Res. 2000;103:57-75. doi: 10.1007/978-1-4757-3147-7_4. Cancer Treat Res. 2000. PMID: 10948442 Review. No abstract available.

3

Trastuzumab and chemotherapeutics: drug interactions and synergies.

Pegram MD, Lopez A, Konecny G, Slamon DJ. Pegram MD, et al. Semin Oncol. 2000 Dec;27(6 Suppl 11):21-5; discussion 92-100. Semin Oncol. 2000. PMID: 11236023

4

Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.

Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M. Konecny G, et al. Clin Cancer Res. 2001 Jun;7(6):1743-9. Clin Cancer Res. 2001. PMID: 11410515

5

Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.

Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M. Konecny G, et al. Clin Cancer Res. 2001 Aug;7(8):2448-57. Clin Cancer Res. 2001. PMID: 11489825

6

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.

Konecny G, Untch M, Slamon D, Beryt M, Kahlert S, Felber M, Langer E, Lude S, Hepp H, Pegram M. Konecny G, et al. Breast Cancer Res Treat. 2001 Jun;67(3):223-33. doi: 10.1023/a:1017980411398. Breast Cancer Res Treat. 2001. PMID: 11561768

7

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer.

Konecny G, Fritz M, Untch M, Lebeau A, Felber M, Lude S, Beryt M, Hepp H, Slamon D, Pegram M. Konecny G, et al. Breast Cancer Res Treat. 2001 Sep;69(1):53-63. doi: 10.1023/a:1012226006395. Breast Cancer Res Treat. 2001. PMID: 11759828

8

HER2 testing and correlation with efficacy of trastuzumab therapy.

Konecny G, Slamon DJ. Konecny G, et al. Oncology (Williston Park). 2002 Nov;16(11):1576, 1578. Oncology (Williston Park). 2002. PMID: 12469932 No abstract available.

9

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Konecny G, et al. J Natl Cancer Inst. 2003 Jan 15;95(2):142-53. doi: 10.1093/jnci/95.2.142. J Natl Cancer Inst. 2003. PMID: 12529347

10

Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?

Konecny GE, Wilson CA, Slamon DJ. Konecny GE, et al. J Natl Cancer Inst. 2003 Dec 17;95(24):1813-5. doi: 10.1093/jnci/djg134. J Natl Cancer Inst. 2003. PMID: 14679144 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Search Page

Filters